We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UnitedHealth Group (UNH) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Read MoreHide Full Article
UnitedHealth Group (UNH - Free Report) ended the recent trading session at $280.44, demonstrating a -1.37% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.28% for the day. Meanwhile, the Dow lost 0.44%, and the Nasdaq, a tech-heavy index, lost 0.28%.
The largest U.S. health insurer's stock has dropped by 1.34% in the past month, exceeding the Medical sector's loss of 7.53% and the S&P 500's loss of 3.59%.
Investors will be eagerly watching for the performance of UnitedHealth Group in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on April 21, 2026. It is anticipated that the company will report an EPS of $6.76, marking a 6.11% fall compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $110.26 billion, up 0.62% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.7 per share and revenue of $440.44 billion, indicating changes of +8.26% and -1.59%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for UnitedHealth Group. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.02% rise in the Zacks Consensus EPS estimate. UnitedHealth Group is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, UnitedHealth Group is presently being traded at a Forward P/E ratio of 16.07. This denotes no noticeable deviation relative to the industry average Forward P/E of 16.07.
It is also worth noting that UNH currently has a PEG ratio of 1.31. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - HMOs industry had an average PEG ratio of 0.93.
The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 226, which puts it in the bottom 8% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
UnitedHealth Group (UNH) Sees a More Significant Dip Than Broader Market: Some Facts to Know
UnitedHealth Group (UNH - Free Report) ended the recent trading session at $280.44, demonstrating a -1.37% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.28% for the day. Meanwhile, the Dow lost 0.44%, and the Nasdaq, a tech-heavy index, lost 0.28%.
The largest U.S. health insurer's stock has dropped by 1.34% in the past month, exceeding the Medical sector's loss of 7.53% and the S&P 500's loss of 3.59%.
Investors will be eagerly watching for the performance of UnitedHealth Group in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on April 21, 2026. It is anticipated that the company will report an EPS of $6.76, marking a 6.11% fall compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $110.26 billion, up 0.62% from the prior-year quarter.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.7 per share and revenue of $440.44 billion, indicating changes of +8.26% and -1.59%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for UnitedHealth Group. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.02% rise in the Zacks Consensus EPS estimate. UnitedHealth Group is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, UnitedHealth Group is presently being traded at a Forward P/E ratio of 16.07. This denotes no noticeable deviation relative to the industry average Forward P/E of 16.07.
It is also worth noting that UNH currently has a PEG ratio of 1.31. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. By the end of yesterday's trading, the Medical - HMOs industry had an average PEG ratio of 0.93.
The Medical - HMOs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 226, which puts it in the bottom 8% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.